



**FOR IMMEDIATE RELEASE**

**MERRIMACK PHARMACEUTICALS ANNOUNCES THE ADDITION OF  
BARRETT ROLLINS, MD, PhD TO ITS SCIENTIFIC ADVISORY BOARD**

**Cambridge, MA – February 28, 2006.** Barrett Rollins, M.D., Ph.D. has joined the Scientific Advisory Board (SAB) of Merrimack Pharmaceuticals, Inc. Dr. Rollins is the Chief Scientific Officer at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School. Since starting at Dana-Farber in 1989, Dr. Rollins has worked in the area of white blood cell trafficking and maintained a scientific interest in lung cancer.

“Dr. Rollins is an outstanding scientist in his field and a great addition to our SAB,” stated Vincent F. Simmon, Ph.D., COO of Merrimack. “His expertise in oncology will be extremely helpful as we evaluate drugs that are emerging from our Network Biology Platform.”

Dr. Rollins will be joining SAB members Peter K. Sorger, Ph.D., Professor of Biology and Professor of Biological Engineering, MIT (Chairman of the SAB), Douglas Lauffenburger, Ph.D., Uncas & Helen Whitaker Professor of Bioengineering, MIT, Dan R. Littman, M.D., Ph.D., Helen L. and Martin S. Kimmel Professor of Molecular Immunology and Professor of Pathology and Microbiology, Skirball Institute, NYU, Gavin MacBeath, Ph.D., Assistant Professor, Department of Chemistry and Chemical Biology, Harvard University, James D. Marks, M.D., Ph.D., Professor, Anesthesia and Pharmaceutical Chemistry, Program Member UCSF Comprehensive Cancer Center, UCSF, and Associate Director, Medical-Surgical Intensive Care Unit, San Francisco General Hospital, and Michael Yaffe, M.D., Ph.D., Associate Professor of Biology, MIT.

“We are very pleased to have Dr. Rollins join the Merrimack SAB,” noted Dr. Sorger. “As a physician scientist, Barrett has the ideal combination of clinical and scientific expertise to help Merrimack to achieve its goal of developing novel therapeutics and associated diagnostics. This approach should lead to new oncology products and personalized treatments that maximize patient response. Merrimack’s approach to unmet medical needs combines high throughput assay methods and computational modeling. This network biology approach is expected to accelerate the rate of drug discovery.”

Contact: James S. Scibetta, Executive VP & CFO  
617-441-1043

*Merrimack Pharmaceuticals, Inc. is a privately held biotechnology company focused on the discovery and development of novel treatments for diseases in the areas of autoimmune disease and cancer. Its lead compound, MM-093, is currently in Phase 2 clinical development to treat patients with rheumatoid arthritis or with psoriasis. MM-093 is an investigational drug and has not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and safe therapeutics. Merrimack is based in Cambridge, Massachusetts. For additional information, please visit [www.merrimackpharma.com](http://www.merrimackpharma.com).*

\*\*\*\*\*